Drugs / TAcs
last change Oct 2019 re-read 2 minutes ago

TAcs

Developed for
osteoarthritis, knee

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03378076 Comparator Dec 2017 → Mar 2018 osteoarthritis, knee Pacira Pharmaceuticals, Inc Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as TAcs ClinicalTrials.gov intervention name — accepted as the source's own label NCT03378076
Known as Triamcinolone Acetonide Crystalline Suspension (TAcs) Triamcinolone Acetonide Crystalline Suspension (TAcs)NCT03378076
Route Other “received concurrent single intra-articular injections of TA-ER 32 mg or TAcs 40 mg into each knee” PMID 31662801 Oct 2019